David Liew drdavidliew
3 years 10 months ago
Ultrasound and MRI have taught us a lot about PMR, but it's the power of PET/CT which illustrated the specific pathology of PMR in full color vision.
@drceowen #ACR22 @RheumNow https://t.co/N8hVjqpVwe
Eric Dein ericdeinmd
3 years 10 months ago
14M111 Updated ACR Guidelines for Glucocorticoid-Induced Osteoporosis #ACR22 🦴🦴
Initial Fracture Risk Assessment - by age - remember: no FRAX scores <40 yo
Fracture re-assessments every 1-2 years with repeat BMD and risk stratifications
@RheumNow https://t.co/QlCVM1lDb0
Aurelie Najm AurelieRheumo
3 years 10 months ago
BE OPTIMAL: BKZ in PsA Phase 3 RCT
Data at 52 wks 700+ completed study
ACR50: 53% PBO/BKZ, 54% BKZ, 50% ADA
PASI 100 65% PBO/BKZ, 61% BKZ, 48% ADA
No Rx progression 87% PBO/BKZ, 89% BKZ, 94% ADA
Candida infections 7% BKZ, 0.7% ADA
https://t.co/MMjN1Aa3qf
Abs#L02 #ACR22 @Rheumnow https://t.co/keF0QOZMwA
TheDaoIndex KDAO2011
3 years 10 months ago
Dr. B Humphrey #ACR22 #Osteoporosis Guidelines:
in patients under 40 yo, you cannot calculate #FRAX score, assess BMD and in children get also thoracolumbar xrays. Get repeat testing every 1-2 years #ACR22 @rheumnow https://t.co/CgsvzGKYuV
Janet Pope Janetbirdope
3 years 10 months ago
Get the skinny on Bimmy! Gotta learn this name #Bimekizumab in bio naive PsA N=852 Bimmy=IL17 A & F inhibitor Great data on skin & joints. Where will it fit in as we have other IL17Ai’s is IL17F giving added value? #ACR22 #ACRBest @RheumNow https://t.co/wNAzTaLhsM
Aurelie Najm AurelieRheumo
3 years 10 months ago
800+ women w/ IMID & 1700+ ctrl w/ 6 yrs follow-up
All GC users < BMD levels
-4.2% > 2.5mg/d
-2.7% <2.5mg/d
Crude FX rate 4.8/100PY GC >= 5mg/d, 2.5/100PY GC < 2.5mg/d
🦴Fx incidence > IMID vs. Ctrls
GC use >= 5mg/d x2 risk of Fx
https://t.co/6sj77PwyYQ
Abs#L01 #ACR22 @Rheumnow https://t.co/OZhfuh0Jrm
There has been a lot of talk lately about the difference in the way male and female PsA patients experience their disease. Are the differences only cultural or are there important clinical differences in the disease presentation, organ involvement and complications that physicians should be aware of?
Eric Dein ericdeinmd
3 years 10 months ago
14M111 Updated ACR Guidelines for Glucocorticoid-Induced Osteoporosis #ACR22 🦴🦴
Reminder: Recalculate FRAX scores with scaling for prednisone equivalent dosing!
Use other clinical fracture risk assessments
@RheumNow https://t.co/qZDlb1Cij7
TheDaoIndex KDAO2011
3 years 10 months ago
Dr. B Humphrey #ACR22 #Osteoporosis Guidelines:
FRAX needs to be adjusted according to the dose of GC's (7.5+ mg/day multiply FRAX score by 1.2)
#ACR22 @rheumnow https://t.co/U7IOjbTwxN
Olga Petryna DrPetryna
3 years 10 months ago
#L01 #acr22 @rheumnow chronic GC use in rheum Dx assoctd w/⬇️ T scores & ⬆️fracture even if dose 2.5 mg or less. GC use ≥5 mg/day associated w/ 2-fold higher risk of fracture of any kind compared to all other doses& controls (aHR 2.37, 95% CI 1.33-4.23).Preventable w/anti-OP Rx https://t.co/sCWkEBPMMT
Richard Conway RichardPAConway
3 years 10 months ago
Almayali et al. Follow-up of GLORIA study. Now tapering of the pred 5mg after 2 years. Small increase in disease activity (to same level as prev placebo), numerical increase in flare. No adrenal insufficiency @RheumNow #ACR22 Abstr#2000 https://t.co/5oclSdlXWA https://t.co/HT2pmsxPiC
Richard Conway RichardPAConway
3 years 10 months ago
Wow! Walrabenstein et al. RCT of plant-based diet (and exercise and stress management) vs usual care in low-moderate disease activity RA. It worked! But which of the 3 parts of the intervention was responsible? @RheumNow #ACR22 Abstr#1998 https://t.co/X1f07ZWPjU https://t.co/nkM4misfFW
Richard Conway RichardPAConway
3 years 10 months ago
Yokose et al. Higher risk of mortality in women with gout. Primarily CVD related death. @RheumNow #ACR22 Abstr#1757 https://t.co/Ft3Km8Jw17 https://t.co/uBOUnV4n0Z
Richard Conway RichardPAConway
3 years 10 months ago
Haibel et al. Intraarticular morphine no different to placebo and inferior to steroid in knee OA. @RheumNow #ACR22 Abstr#1833 https://t.co/9dOlfYMVlj https://t.co/a3uvw3gVw3
Richard Conway RichardPAConway
3 years 10 months ago
Kivitz et al. Phase 2 RCT Dazodalibep (non-antibody biologic antagonist of CD40L) in csDMARD/bDMARD-IR RA. Improve DAS28-CRP, CDAI, SDAI, TJC, SJC at day 113. @RheumNow #ACR22 Abstr#2008 https://t.co/RwRbeFC4rt https://t.co/F8bEI1lZGM
